スピロノラクトン：女性型脱毛症

Q: Does スピロノラクトン help with 女性型脱毛症?

Based on 45 studies with 6,441 participants, there is strong evidence from multiple clinical trials that スピロノラクトン may support 女性型脱毛症 management. Our evidence grade is A (Strong Evidence).

Q: How much スピロノラクトン should I take for 女性型脱毛症?

Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.

Q: Are there side effects of スピロノラクトン?

Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

Q: How strong is the evidence for スピロノラクトン and 女性型脱毛症?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,441 total participants. The overall direction of effect is positive.

合計5,743名の参加者を対象とした19件の研究（メタアナリシス2件、RCT 4件を含む）に基づく。19件中16件の研究で肯定的な効果が示されている。

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dspironolactone\u0026condition\u003Dfemale\u002Dpattern\u002Dhair\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Spironolactone is strongly supported by research as an effective option that may help women with female pattern hair loss, with both oral and topical formulations showing benefits in clinical trials.

84% of studies show positive effects, including 4 RCTs focused on women
Both oral and topical formulations have demonstrated benefits
A dedicated meta-analysis confirms efficacy and safety in female pattern hair loss
Combination with minoxidil may offer enhanced results

Key Study Findings

Review

Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.

Dose: None vs: None Outcome: None 効果: None None

対象集団: women with androgenetic alopecia (female pattern hair loss)

Randomized Controlled Trial n=204 24 weeks Double-blind

Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial.

Dose: Bicalutamide 50 mg/day; spironolactone 100 mg/day vs: Spironolactone 100 mg/day Outcome: Hair density and shaft diameter change at 24 … 効果: Frontal: +5.05 vs +3.13 hairs/cm2 (diff 1.92) P < 0.001 (frontal); P = 0.028

対象集団: Women 18-50 with Sinclair Grade II-V FPHL (India)

randomized controlled trial n=80 24 weeks Single-blind

Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment …

Dose: Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily vs: Placebo 効果: Both groups showed statistically significant improvement. Group A: 10 mild, 16 moderate, 2 excellent None

RCT n=48 24 weeks Double-blind

Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a …

Dose: Spironolactone 100 mg once daily vs: Placebo 効果: Terminal hair counts: 9.48 vs 5.32 hairs/cm2; hair diameter: 4.23 vs 2.96 μm; moderate-to-marked imp p=0.063 (terminal hair counts)

Randomized Controlled Trial n=240 520 weeks Open-label

Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of …

Dose: None vs: Laparoscopic Roux-en-Y gastric bypass (LRYGB) Outcome: Nutritional deficiency prevalence at 10 years 効果: Iron deficiency: LSG 14% vs LRYGB 41% p=0.017 (iron deficiency)

対象集団: Severely obese adults undergoing bariatric surgery

Review

Male and female pattern hair loss.

Dose: None vs: Placebo 効果: None None

Key Statistics

研究数

6441

参加者数

↑

Positive

グレード

Referenced Papers

Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial. Other

Clinical and experimental … 2026

Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. Review

American journal of … 2026

Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of the SLEEVEPASS randomized clinical trial. RCT

The British journal … 2025 10 件の引用

Spironolactone reduces the risk of low-dose oral minoxidil-induced edema in women with female pattern hair loss. Other

Journal of the … 2025 3 件の引用

Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot … Other

International journal of … 2025 3 件の引用

Male and female pattern hair loss. Review

Australian prescriber 2025 2 件の引用

Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment. Other

Dermatology practical & … 2025 1 件の引用

Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment of Female Pattern Hair Loss: … Other

International journal of … 2025

Pharmacokinetics behavior of four cannabidiol preparations following single oral administration in dogs. Other

Frontiers in veterinary … 2024 15 件の引用

The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral … RCT

Journal of cosmetic … 2024 14 件の引用

Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. Review

Journal of clinical … 2024 11 件の引用

Efficacy and safety of spironolactone versus bicalutamide in female pattern hair loss: A retrospective comparative study. Other

The Australasian journal … 2024 5 件の引用

Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management. Other

Archives of dermatological … 2024 4 件の引用

Inter-strain variability in responses to a single administration of the cannabidiol-rich cannabis extract in mice. Other

Food and chemical … 2024 1 件の引用

Improving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy: A retrospective … Other

JAAD international 2024 1 件の引用

The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. Review

Cureus 2023 13 件の引用

Combination therapy in female pattern hair loss. Review

Journal of cosmetic … 2023 3 件の引用

Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension … Other

Journal of personalized … 2022 16 件の引用

Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: … Case Report

Frontiers in medicine 2022 14 件の引用

Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative … Other

PEC innovation 2022 11 件の引用

Spironolactone for treatment of female pattern hair loss. Other

Journal of the … 2020 43 件の引用

Spironolactone in dermatology: uses in acne and beyond. Review

Clinical and experimental … 2020 20 件の引用

Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind … Other

Dermatology practical & … 2020 10 件の引用

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. Meta-Analysis

The Journal of … 2019 101 件の引用

Androgens in women: Androgen-mediated skin disease and patient evaluation. Review

Journal of the … 2019 95 件の引用

Androgens in women: Hormone-modulating therapies for skin disease. Review

Journal of the … 2019 55 件の引用

Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Review

Breast cancer research … 2019 36 件の引用

Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. Other

Polski merkuriusz lekarski … 2019 4 件の引用

Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Observational

International journal of … 2018 142 件の引用

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Review

International journal of … 2018 129 件の引用

Female pattern hair loss. Other

Australian journal of … 2018 8 件の引用

Interventions for female pattern hair loss. Meta-Analysis

The Cochrane database … 2016 18 件の引用

Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. Review

The Medical clinics … 2015 66 件の引用

Evidence-based approach to cutaneous hyperandrogenism in women. Review

Journal of the … 2015 50 件の引用

Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. Other

Journal of the … 2015 43 件の引用

Hair loss in women. Review

Clinical obstetrics and … 2015 9 件の引用

Female pattern hair loss. Review

Current problems in … 2015 8 件の引用

[Spironolactone in dermatological treatment. On and off label indications]. Other

Der Hautarzt; Zeitschrift … 2013 19 件の引用

Female pattern alopecia: current perspectives. Review

International journal of … 2013

Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Review

The British journal … 2011 96 件の引用

Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. Case Report

The Australasian journal … 2011 44 件の引用

Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Other

Dermatologic clinics 2010 80 件の引用

Use of spironolactone in dermatology. Review

Skinmed 2010 33 件の引用

Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. Case Report

The Australasian journal … 2009 31 件の引用

Hair loss in women. Review

Seminars in cutaneous … 2009 4 件の引用

Treating female pattern hair loss. Noticeable hair loss can be deeply distressing. Here are some medical treatments that may help. Other

Harvard women's health … 2009

A review of hormonal therapy for female pattern (androgenic) alopecia. Review

Dermatology online journal 2008

Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Case Report

The Australasian journal … 2007 32 件の引用

[The treatment of female pattern hair loss]. Review

Duodecim; laaketieteellinen aikakauskirja 2006

Evaluation and treatment of male and female pattern hair loss. Other

Journal of the … 2005 247 件の引用

Treatment of female pattern hair loss with oral antiandrogens. Other

The British journal … 2005 205 件の引用

Chronic telogen effluvium: a study of 5 patients over 7 years. Case Report

Journal of the … 2005 64 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

hairloss:: 100-200 mg/day (prescription)

上限量： 200 mg/day (hair loss indication)

研究で検討された用量

用量	期間	効果	N
None	--	Neutral	--
Bicalutamide 50 mg/day; spironolactone 100 mg/day	24 weeks	Positive	204
Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily	24 weeks	Positive	80
Spironolactone 100 mg once daily	24 weeks	Positive	48
None	520 weeks	Positive	240
None	--	Positive	--
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi	16 weeks	Positive	45
4 g	--	Neutral	--

推奨摂取タイミング： Once or twice daily with food; prescription required

Safety & Side Effects

報告されている副作用

⚠ Menstrual irregularities
⚠ Breast tenderness
⚠ Hyperkalemia (elevated potassium levels)
⚠ Dizziness and orthostatic hypotension
⚠ Frequent urination

既知の相互作用

● ACE inhibitors and ARBs (increased hyperkalemia risk)
● Potassium supplements and potassium-sparing diuretics (dangerous hyperkalemia)
● NSAIDs (may reduce diuretic effectiveness and increase kidney risk)
● Digoxin (spironolactone may increase digoxin levels)

耐容上限摂取量： 200 mg/day (hair loss indication)

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does スピロノラクトン help with 女性型脱毛症?

Based on 45 studies with 6,441 participants, there is strong evidence from multiple clinical trials that スピロノラクトン may support 女性型脱毛症 management. Our evidence grade is A (Strong Evidence).

How much スピロノラクトン should I take for 女性型脱毛症?

Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of スピロノラクトン?

Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for スピロノラクトン and 女性型脱毛症?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,441 total participants. The overall direction of effect is positive.

Related Evidence

に関する他の成分：女性型脱毛症

ミノキシジル A ビタミンD A 低出力レーザー治療 A ニュートラフォル A ノコギリヤシ B

スピロノラクトン他の症状・状態について

男性型・女性型脱毛症（AGA） A

総合評価

合計5,743名の参加者を対象とした19件の研究（メタアナリシス2件、RCT 4件を含む）に基づく。19件中16件の研究で肯定的な効果が示されている。

Evidence Strength92%

High confidence

研究の内訳

RCT (2)Meta (2)Other (41)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る：女性型脱毛症

詳しく見る

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。